AU2014239309B2 - miRNA biogenesis in exosomes for diagnosis and therapy - Google Patents

miRNA biogenesis in exosomes for diagnosis and therapy Download PDF

Info

Publication number
AU2014239309B2
AU2014239309B2 AU2014239309A AU2014239309A AU2014239309B2 AU 2014239309 B2 AU2014239309 B2 AU 2014239309B2 AU 2014239309 A AU2014239309 A AU 2014239309A AU 2014239309 A AU2014239309 A AU 2014239309A AU 2014239309 B2 AU2014239309 B2 AU 2014239309B2
Authority
AU
Australia
Prior art keywords
mir
hsa
mmu
exosomes
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014239309A
Other languages
English (en)
Other versions
AU2014239309A1 (en
Inventor
Raghu Kalluri
Sonia MELO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
University of Texas System
Original Assignee
Beth Israel Deaconess Medical Center Inc
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, University of Texas System, University of Texas at Austin filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2014239309A1 publication Critical patent/AU2014239309A1/en
Application granted granted Critical
Publication of AU2014239309B2 publication Critical patent/AU2014239309B2/en
Priority to AU2020203590A priority Critical patent/AU2020203590B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AU2014239309A 2013-03-15 2014-03-14 miRNA biogenesis in exosomes for diagnosis and therapy Ceased AU2014239309B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203590A AU2020203590B2 (en) 2013-03-15 2020-06-01 Mirna biogenesis in exosomes for diagnosis and therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791301P 2013-03-15 2013-03-15
US61/791,301 2013-03-15
PCT/US2014/027541 WO2014152622A1 (en) 2013-03-15 2014-03-14 Mirna biogenesis in exosomes for diagnosis and therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203590A Division AU2020203590B2 (en) 2013-03-15 2020-06-01 Mirna biogenesis in exosomes for diagnosis and therapy

Publications (2)

Publication Number Publication Date
AU2014239309A1 AU2014239309A1 (en) 2015-10-08
AU2014239309B2 true AU2014239309B2 (en) 2020-03-05

Family

ID=51581257

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014239309A Ceased AU2014239309B2 (en) 2013-03-15 2014-03-14 miRNA biogenesis in exosomes for diagnosis and therapy
AU2020203590A Active AU2020203590B2 (en) 2013-03-15 2020-06-01 Mirna biogenesis in exosomes for diagnosis and therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203590A Active AU2020203590B2 (en) 2013-03-15 2020-06-01 Mirna biogenesis in exosomes for diagnosis and therapy

Country Status (15)

Country Link
US (2) US20160024503A1 (https=)
EP (2) EP2971162B1 (https=)
JP (2) JP6554458B2 (https=)
KR (1) KR102183406B1 (https=)
CN (2) CN105264092B (https=)
AU (2) AU2014239309B2 (https=)
BR (1) BR112015023275B1 (https=)
CA (2) CA2905081C (https=)
ES (1) ES2966571T3 (https=)
HK (1) HK1218143A1 (https=)
IL (2) IL241409B (https=)
MX (2) MX373957B (https=)
PT (1) PT3527670T (https=)
RU (2) RU2018101152A (https=)
WO (1) WO2014152622A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016150475A1 (en) * 2015-03-22 2016-09-29 Universite De Liege Circulating micrornas for the diagnosis of breast cancer
CN104774966B (zh) * 2015-05-01 2017-07-28 北京博奥医学检验所有限公司 肺腺癌miRNA标记物
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
CN107151661A (zh) * 2016-03-02 2017-09-12 上海润腾生物科技有限公司 一种人外泌体蛋白、试剂盒及其应用
CN106202984B (zh) * 2016-08-26 2018-09-04 赵毅 一种基于多层复杂网络对肿瘤miRNA标志物的筛选方法
WO2018071806A1 (en) * 2016-10-13 2018-04-19 University Of Louisville Research Foundation, Inc. Exosomal biomarkers for diagnosis and prognosis of cancer and related methods
US11783918B2 (en) 2016-11-30 2023-10-10 Microsoft Technology Licensing, Llc DNA random access storage system via ligation
US10793897B2 (en) * 2017-02-08 2020-10-06 Microsoft Technology Licensing, Llc Primer and payload design for retrieval of stored polynucleotides
CA3083140A1 (en) * 2017-11-30 2019-06-06 Provincial Health Services Authority Methods for evaluating head and neck cancers
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
US11648260B2 (en) 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
US11364280B2 (en) * 2018-04-17 2022-06-21 Taipei Veterans General Hospital Method for blocking stress-induced tumor progression
CA3098105A1 (en) 2018-04-25 2019-10-31 Toray Industries, Inc. Kit, device, and method for detecting bladder cancer
JP7710849B2 (ja) 2018-10-17 2025-07-22 合同会社Ｈ．Ｕ．グループ中央研究所 細胞外小胞の回収方法
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
US20220136011A1 (en) 2019-02-08 2022-05-05 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
WO2020163553A1 (en) * 2019-02-08 2020-08-13 Virginia Commonwealth University Mda-7/il-24 for cancer treatment and methods of monitoring same
CN118512469A (zh) * 2019-02-26 2024-08-20 首尔大学校产学协力团 包含末端尿苷酰基转移酶4/7表达调控因子的用于预防或治疗癌症的药学组合物
AU2020299633B2 (en) * 2019-07-02 2026-03-26 Ohio State Innovation Foundation Neurodegenerative disease therapies utilizing the skin-brain axis
US20220275455A1 (en) * 2019-07-08 2022-09-01 Preferred Networks, Inc. Data processing and classification for determining a likelihood score for breast disease
CN110358835A (zh) * 2019-07-26 2019-10-22 泗水县人民医院 生物标志物在胃癌检测、诊断中的应用
KR102212699B1 (ko) * 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
CN110607361A (zh) * 2019-10-08 2019-12-24 南京市儿童医院 miR-431作为靶点在制备促进SP表达的药物中的应用
US20230051797A1 (en) 2019-12-23 2023-02-16 Fujirebio Inc. Method for recovering extracellular vesicle and blood collection vessel
EP3862442A3 (en) * 2020-02-04 2021-10-27 Artemisia S.p.A. Method for the early diagnosis of cancer by means of ddpcr analysis of mirna in liquid biopsy
EP3862441A3 (en) * 2020-02-04 2021-10-27 Artemisia S.p.A. Method for the early diagnosis of cancer by means of ddpcr analysis of mirna and protein markers in liquid biopsy
KR102318328B1 (ko) * 2020-04-13 2021-10-27 고려대학교 산학협력단 Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물
US20230227916A1 (en) 2020-04-15 2023-07-20 H.U. Group Research Institute G.K. Method for recovering extracellular vesicle
CN111920961B (zh) * 2020-08-14 2023-09-08 福建医科大学附属协和医院 一种治疗癌症的药物
KR102497196B1 (ko) 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
EP4212632A4 (en) * 2020-09-08 2024-07-17 Urotech. Co., Ltd. METHODS FOR CALCULATION OF THE DIAGNOSTIC PROSTATE CANCER SCORE AND USES THEREOF
WO2022102246A1 (ja) * 2020-11-11 2022-05-19 国立研究開発法人物質・材料研究機構 細胞で産生された膜小胞に由来する塩基配列を解析する方法、その装置、及び、そのプログラム
CN112662752B (zh) * 2021-01-18 2022-08-23 中国农业大学 一种诊断用生物标志物的应用
KR102310302B1 (ko) * 2021-02-08 2021-10-06 을지대학교 산학협력단 엑소좀 기반 방광암 진단을 위한 정보 제공 방법
CN112760381B (zh) * 2021-02-08 2022-11-01 复旦大学附属中山医院 一种检测肺腺癌预后的miRNA试剂盒
CN117802235B (zh) * 2022-09-30 2025-08-19 上海思路迪生物医学科技有限公司 血液胞外囊泡miRNA在卵巢癌诊断中的应用
CN116121377A (zh) * 2022-11-01 2023-05-16 山西医科大学 一种食管鳞癌外泌体富含的miRNA作为诊断食管鳞癌的标志物中的应用
CN117778574B (zh) * 2023-12-25 2024-09-03 山东中医药大学 Mir937基因组拷贝数扩增在卵巢癌诊断和/或治疗中的应用
CN118421798B (zh) * 2024-05-22 2025-02-07 南通市海门区人民医院 用于检测结直肠癌相关血清生物标志物、sers传感器及制备方法
EP4667011A1 (en) * 2024-06-17 2025-12-24 Bios-Therapy, Physiological Systems for Health S.p.A. Epigenau/11: a natural matrix with therapeutic activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064949A1 (en) 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
CN1281279C (zh) * 2004-09-16 2006-10-25 浙江大学 针对表皮生长因子基因的小干扰核糖核酸分子及其用途
EP2610342B1 (en) * 2007-09-14 2016-05-04 The Ohio State University Research Foundation MiRNA Expression in Human Peripheral Blood Microvesicles and uses Thereof
CN106310293A (zh) * 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
KR101810799B1 (ko) 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
CN102027129B (zh) * 2008-02-28 2014-03-12 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
WO2009126563A1 (en) * 2008-04-11 2009-10-15 The University Of North Carolina At Chapel Hill Methods and compositions for the regulation of microrna processing
WO2009147519A1 (en) * 2008-06-06 2009-12-10 Centre National De La Recherche Scientifique - Cnrs- Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
JP2013526852A (ja) * 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2011133504A2 (en) 2010-04-20 2011-10-27 University Of Florida Research Foundation, Inc. Nanozymes, methods of making nanozymes, and methods of using nanozymes
US9901600B2 (en) * 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
CA2871089A1 (en) * 2011-04-20 2012-10-26 Smith Holdings, Llc Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
US9777042B2 (en) 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
US9921223B2 (en) 2013-12-04 2018-03-20 Board Of Regents, The University Of Texas System Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis
HUE059718T2 (hu) * 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker

Also Published As

Publication number Publication date
CN105264092B (zh) 2019-02-22
MX2020005165A (es) 2020-08-20
RU2644247C2 (ru) 2018-02-08
US11926824B2 (en) 2024-03-12
IL273829B (en) 2021-12-01
EP2971162A1 (en) 2016-01-20
IL241409A0 (en) 2015-11-30
US20200255831A1 (en) 2020-08-13
CA3209023A1 (en) 2014-09-25
AU2020203590A1 (en) 2020-06-18
PT3527670T (pt) 2024-01-18
MX2015013141A (es) 2016-06-21
ES2966571T3 (es) 2024-04-23
JP2016520803A (ja) 2016-07-14
RU2015144212A (ru) 2017-04-21
IL241409B (en) 2020-04-30
JP2018138057A (ja) 2018-09-06
RU2018101152A3 (https=) 2019-02-21
RU2018101152A (ru) 2019-02-21
CN109852695A (zh) 2019-06-07
EP3527670A1 (en) 2019-08-21
JP6554458B2 (ja) 2019-07-31
KR102183406B1 (ko) 2020-12-11
EP3527670B1 (en) 2023-10-18
JP6807351B2 (ja) 2021-01-06
KR20160006673A (ko) 2016-01-19
WO2014152622A1 (en) 2014-09-25
AU2014239309A1 (en) 2015-10-08
AU2020203590B2 (en) 2023-06-22
CN109852695B (zh) 2023-11-21
CA2905081C (en) 2023-10-03
IL273829A (en) 2020-05-31
MX373957B (es) 2020-07-13
US20160024503A1 (en) 2016-01-28
BR112015023275B1 (pt) 2022-06-21
EP2971162A4 (en) 2016-11-16
BR112015023275A8 (pt) 2018-01-23
BR112015023275A2 (pt) 2017-07-18
HK1218143A1 (zh) 2017-02-03
EP2971162B1 (en) 2019-05-08
CN105264092A (zh) 2016-01-20
CA2905081A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
AU2020203590B2 (en) Mirna biogenesis in exosomes for diagnosis and therapy
Iorio et al. MicroRNA gene expression deregulation in human breast cancer
Yu et al. MicroRNA alterations of pancreatic intraepithelial neoplasias
JP5976726B2 (ja) 前立腺関連障害の予後診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
US9315809B2 (en) Differentially expressed microRNA molecules for the treatment and diagnosis of cancer
Yao et al. Novel molecular beacons to monitor microRNAs in non-small-cell lung cancer
Luo et al. MicroRNA in prostate cancer: from biogenesis to applicative potential
Miguel The extracellular miRNA fingerprint of kidney disease: A narrative review
INCHE ZAINAL ABIDIN Role of MicroRNAs in determining the cancer-associated fibroblast phenotype
Liu MicroRNA regulation of prostate cancer stem/progenitor cells and prostate cancer development
Gordanpour MicroRNAs as Prognostic Biomarkers in Prostate Cancer
Yang Molecular and Functional Characterization of MicroRNA-137 in Oligodendroglial Tumors
Elgamal Transcriptional and Post Transcriptional Regulation of Gene Expression: Applications to Biology and Cancer
Armstrong The differential expression of miRNAs in breast cancer cell-lines upon autophagy induction
Della Vittoria Scarpati New biomolecular prognostic and predictive factors of response to treatment in colo-rectal cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired